Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Sponsor
GlaxoSmithKline
Study ID
NCT06655818
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination treatment to explore in the cohort expansion phase. This study is a sub study of the Master protocol (NCT04126200).

Key Dates

Start date
Mar 9, 2021
Status verified
Feb 2025
Primary completion
Feb 14, 2024
Completion
Feb 14, 2024

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Belantamab mafodotin + Dostarlimab

Primary Outcome Measure

DE Phase: Number of Participants With Dose Limiting Toxicities (DLT) [ Time Frame: Up to 21 days ]

Related Studies